Boston Scientific Corporation $BSX Shares Acquired by NewEdge Wealth LLC

NewEdge Wealth LLC increased its holdings in Boston Scientific Corporation (NYSE:BSX) by 15.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 72,616 shares of the medical equipment provider’s stock after buying an additional 9,917 shares during the period. NewEdge Wealth LLC’s holdings in Boston Scientific were worth $6,924,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of Boston Scientific by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after buying an additional 1,436,550 shares during the period. Invesco Ltd. boosted its holdings in shares of Boston Scientific by 0.7% in the 3rd quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock valued at $1,656,131,000 after buying an additional 111,826 shares during the period. Northern Trust Corp boosted its holdings in shares of Boston Scientific by 0.9% in the 3rd quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider’s stock valued at $1,406,129,000 after buying an additional 128,188 shares during the period. Amundi boosted its holdings in shares of Boston Scientific by 17.5% in the 3rd quarter. Amundi now owns 11,981,584 shares of the medical equipment provider’s stock valued at $1,158,619,000 after buying an additional 1,781,830 shares during the period. Finally, Legal & General Group Plc boosted its holdings in shares of Boston Scientific by 4.6% in the 3rd quarter. Legal & General Group Plc now owns 10,457,175 shares of the medical equipment provider’s stock valued at $1,020,934,000 after buying an additional 463,889 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Weiss Ratings lowered shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, February 4th. Oppenheimer set a $90.00 price target on shares of Boston Scientific in a report on Thursday, April 23rd. Stifel Nicolaus decreased their price target on shares of Boston Scientific from $90.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, April 21st. JPMorgan Chase & Co. reduced their target price on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Finally, Morgan Stanley reduced their target price on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $93.91.

Boston Scientific Trading Down 0.1%

Boston Scientific stock opened at $53.89 on Monday. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The firm has a 50-day moving average price of $65.95 and a two-hundred day moving average price of $83.68. The firm has a market capitalization of $80.08 billion, a price-to-earnings ratio of 22.55, a PEG ratio of 0.99 and a beta of 0.62. Boston Scientific Corporation has a 52-week low of $53.63 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. Boston Scientific’s revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.